Skip to content
You are now leaving to visit

Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen

– IONIS-JBI2-2.5 Rx designed to treat GI autoimmune disease – Ionis Earns $5 Million License Fee from Janssen CARLSBAD, Calif. , Nov. 16, 2017 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed a second orally delivered Generation 2.5 antisense drug to